List view / Grid view
A novel CRISPR system that suppresses genes related to adeno-associated virus (AAV) antibody production has been developed to prevent immunity against the gene therapy.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry. However, characterisation of oligos, specifically by ion-pair reversed phase liquid chromatography (IPRPLC), can be quite challenging.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
Silencing RNA, or siRNA, are short, double-stranded RNA molecules which are not only an important research tool in molecular biology, but also an emerging therapeutic modality.
Superficially porous particle technologies provide a reduced diffusion path in comparison with their fully porous counterparts minimising the resistance to mass transfer during chromatographic separation.
A new CRISPR technology has been created to understand mutations based on cytosine to guanine base changes and minimise unintended "off-target" mutations.
The novel CRISPR-CasΦ enzyme, isolated from bacteriophages, can target a wider range of genetic sequences, say the researchers.
Scientists demonstrated that NELL2, a factor release by the testis, is essential for sperm to mature into motile cells able to fertilise an egg.
1 July 2020 | By Phenomenex
In this on-demand webinar, we provide an overview of nucleic acid therapeutics and discuss the chromatographic challenges associated with oligonucleotides. We also explore modulation of the mobile phase additives alkylamine ion pair and perfluorinated alcohols. Finally, we will show how optimisation of mobile phase can improve not only chromatographic performance…
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
15 June 2020 | By Horizon Discovery
Watch our on-demand webinar with Horizon Discovery which summarises the challenges in translating promising pre-clinical therapeutic candidates into clinical success.
A result is only as good as the sample preparation that preceded it.
ESHG 2019: Automated sample preparation using magnetic bead technology and KingFisher instruments.
Automated detection and isolation of pathogens for multiple samples types.
